Skip to content
Menu

ABIVAX Société Anonyme ABVX

Full chart Compare
Set alert

Price alert · ABVX

All alert types
80.35 USD -3.48 (-4.15%)

As ofNov 19, 2026, 3:43 PM EST

80.34 Day range 86.93
69.81 52-week range 148.83
YTD
-40.42%
1 year
-28.86%

5D -5.81 (-6.57%)

82848688FriMonTueWedThu82.62
Market cap
7.03B
Revenue (ttm)
4.67M
EPS (ttm)
-6.08
Shares out
87.54M
Forward P/E
-21.86
YTD return
-40.42%
1-year return
-28.86%
50-day average
93.49
200-day average
112.28
Volume
1.90M
Avg volume
1.11M
Open
83.73
Previous close
83.83
Day's range
80.34 – 86.93
52-week range
69.81 – 148.83
Beta
-0.33
Price target
163.58 (+103.6%)
Earnings date
Dec 21, 2026

Key statistics

Enterprise value
6.15B
Price / sales
1572.11
Price / book
16.26
Revenue growth
-6.80%
Free cash flow
-125.90M
Total cash
402.38M
Total debt
1.21M
Return on equity
-252.35%
Short % of float
4.75%

Fundamental scorecard

3 of 25 checks passed on ABVX’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Jun 30, 2026.

Financials — quick view

All financials
ABVX Revenue — quarterly 1.20M
ABVX Net income — quarterly -117.43M
ABVX EPS — quarterly -1.47

Earnings

ABVX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 21, 2026Sep 30, 2026-0.9199———
Sep 21, 2026Jun 30, 2026-0.97553-1.71-0.73-75.29%
May 22, 2026Mar 31, 2026-1.07-0.71+0.36+33.64%
Mar 23, 2026Dec 31, 2025-1.70-1.19+0.51+30.00%
Dec 15, 2025Sep 30, 2025-0.78649-2.47-1.69-214.27%
Sep 8, 2025Jun 30, 2025-0.90-0.86+0.04+4.44%

Upgrades / downgrades

ABVX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 21, 2026WedbushmainNeutralNeutral
Oct 20, 2026GuggenheimreitBuyBuy
Sep 22, 2026Truist SecuritiesmainBuyBuy
Sep 22, 2026WedbushmainNeutralNeutral
Sep 22, 2026BarclaysmainOverweightOverweight
Sep 10, 2026Goldman Sachsinit—Buy

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Sector
Healthcare
Industry
Biotechnology
Country
France
Website
abivax.com

News

Your note

Sign in to keep a note on ABVX — it syncs with the Stock Master app.

Institution ownership

ABVX institution ownership
Holder% heldSharesValueReported
Helikon Investments Ltd4.82%4,222,896354.01MSep 29, 2026
Darwin Global Management, Ltd.4.59%4,021,583337.13MSep 29, 2026
Vestal Point Capital, LP4.52%3,960,000331.97MSep 29, 2026
TCG Crossover Management, LLC4.18%3,663,038307.07MSep 29, 2026
Janus Henderson Group Ltd.2.45%2,147,116179.99MSep 29, 2026
Adar1 Capital Management, LLC 2.34%2,050,822171.92MSep 29, 2026

Fund ownership

ABVX fund ownership
Holder% heldSharesValueReported
ALGER INSTITUTIONAL FUNDS-Alger Focus Equity Fund0.69%607,57750.93MJul 30, 2026
iShares Trust-iShares Biotechnology ETF0.65%566,95147.53MSep 29, 2026
iShares Trust-iShares Core MSCI EAFE ETF0.56%492,83841.31MSep 29, 2026
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund0.45%394,78233.09MJun 29, 2026
ALGER FUNDS II-Alger Spectra Fund0.38%334,17728.01MJul 30, 2026
HARBOR FUNDS-Harbor Small Cap Growth Fund0.34%296,56024.86MJul 30, 2026